-
Innovation Ranking
NewInnovation Ranking – Sunesis Pharmaceuticals Inc
Viracta Therapeutics Inc (Viracta Therapeutics), develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's pipeline products include Nana-val for the treatment of Lymphoma and Solid Tumors; SSN-510 for the treatment of hematology and solid tumors. The company had partnered programs under development include TAK-580 (formerly MLN2480) and Vosaroxin for the treatment of various types of cancer. The company entered into partnership with Biogen, Takeda, DOT Therapeutics-1, Inc, Denovo Biopharma, LLC for the development of...
-
Product Insights
3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
3 Phosphoinositide Dependent Protein Kinase 1 is an enzyme encoded by the PDPK1 gene, which plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. It negatively regulates the TGF-beta-induced signaling by modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the...
-
Product Insights
Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027
Chronic lymphocytic leukemia (CLL) is a form of cancer that originates from lymphocytes in the bone marrow and later invades the blood and/or lymphoid tissues. CLL treatment has been transformed since the novel oral targeted agents Imbruvica (ibrutinib), Zydelig (idelalisib), and Venclexta (venetoclax) were introduced to the market from 2014 onwards and challenged the prior dominance of chemoimmunotherapy regimens. During the forecast period, the global CLL market will welcome five new drugs—Calquence (acalabrutinib), zanubrutinib, umbralisib, ublituximab, and Revlimid (lenalidomide). The...
-
Product Insights
Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2018" provides an overview of Relapsed Chronic Lymphocytic Leukemia (CLL) clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsed Chronic Lymphocytic Leukemia (CLL). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Sector Analysis
Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU
Market access of oncology medicines is increasingly challenging due to the rising cost of new and innovative medicines, more stringent scientific and value assessments and economic pressures on national budgets and health systems. Although, 5EU markets have implemented patient access schemed to ensure early access to innovative oncology medicines with high unmet need, the increasing requirements for improved clinical benefits and better cost-effectiveness of medicines has resulted in more stringent pricing and reimbursement of medicines leading to access issues such...
-
Product Insights
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...